Skip to content
OpenCapital
Get started

Plus Therapeutics PSTV Q1 2026 earnings

Reported May 15, 2026 · After market close

Revenue$1.0MBeat by $54.0K
EPS-$1.05Miss by $0.10
Revenue estimate$974.0K
EPS estimate-$0.95

Next report

Aug 13, 2026 (In 2 weeks)
Revenue estimate$1.1M
EPS estimate-$0.88

Versus estimates

Revenue

Q1 2026$1.0MBeat by $54.0K
Q4 2025$1.4MBeat by $131.0KQ3 2025$1.4MMiss by $97.8KQ2 2025$1.4MMiss by $96.3KQ1 2025$1.1MMiss by $424.3KQ4 2024$1.4MMiss by $96.0K

Diluted EPS

Q1 2026-$1.05Miss by $0.10
Q4 2025-$0.83Miss by $0.03Q3 2025-$0.04Miss by $0.02Q2 2025-$0.01Beat by $0.08Q1 2025-$0.56Miss by $0.31Q4 2024-$0.67Miss by $0.16

Ask the moment Plus Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Plus Therapeutics report Q1 2026 earnings?
Plus Therapeutics (PSTV) reported Q1 2026 earnings on May 15, 2026 after market close.
What were Plus Therapeutics's Q1 2026 revenue and EPS?
Plus Therapeutics reported revenue of $1.0M and eps of $-1.05 for Q1 2026.
Did Plus Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $974.0K by $54.0K. EPS missed the consensus estimate of $-0.95 by $0.10.
How did Plus Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 2.9% from $1.1M a year earlier and eps declined 87.5% from $-0.56.
Where can I find Plus Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-226747) and the 10-Q periodic report (0001193125-26-226978) directly on SEC EDGAR. The filing index links above go to sec.gov.